Combination therapy — pairing androgen deprivation therapy (ADT) with FDA-approved oral agents — has become a widely used ...

Androgen deprivation therapy is a lifesaving therapy used by thousands of men each year, but some patients are warning of serious mental health risks.

The effectiveness of primary androgen-deprivation therapy (PADT) for clinically localized prostate cancer has been found lacking. A retrospective cohort study of more than 15,000 men newly ...

Pluvicto (lutetium-177 vipivotide tetraxetan) is a radioligand therapy that targets the PSMA protein on prostate cancer cells ...

Combining radiotherapy with androgen deprivation therapy (ADT) is recommended for localized prostate cancer. However, the time required for significant therapeutic benefits is not well quantified.

A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic ...

Androgen deprivation (AD) therapy for prostate cancer is being used in an increasingly wide range of settings, such as advanced disease, loco-regional disease, as an adjunct to surgery or ...

EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission ...

Background: Androgen deprivation therapy (ADT) has been associated with cardiovascular risk in prostate cancer patients. Thus, we performed a systematic review and meta-analysis to assess the ...